Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTP2HE5)

• DTT Name: Tumor associated calcium signal transducer 2 (TACSTD2)
• Synonyms: Cell surface glycoprotein Trop-2; Membrane component chromosome 1 surface marker 1; Pancreatic carcinoma marker protein GA733-1
• Gene Name: TACSTD2
• DTT Type: Clinical trial target; [1]
• UniProt ID: TACD2_HUMAN
• TTD ID: T17629
• Sequence:
  MARGPGLAPPPLRLPLLLLVLAAVTGHTAAQDNCTCPTNKMTVCSPDGPGGRCQCRALGS
  GMAVDCSTLTSKCLLLKARMSAPKNARTLVRPSEHALVDNDGLYDPDCDPEGRFKARQCN
  QTSVCWCVNSVGVRRTDKGDLSLRCDELVRTHHILIDLRHRPTAGAFNHSDLDAELRRLF
  RERYRLHPKFVAAVHYEQPTIQIELRQNTSQKAAGDVDIGDAAYYFERDIKGESLFQGRG
  GLDLRVRGEPLQVERTLIYYLDEIPPKFSMKRLTAGLIAVIVVVVVALVAGMAVLVITNR
  RKSGKYKKVEIKELGELRKEPSL
• Function: May function as a growth factor receptor.

Molecular Interaction Atlas (MIA) of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sacituzumab govitecan	DMUWFD8	Breast cancer	2C60-2C65	Approved	[2]

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SKB264	DMSTEFK	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

1 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
YH012	DMG3WBJ	Aggressive cancer	2A00-2F9Z	Investigative	[3]

References

• [1] ClinicalTrials.gov (NCT04152499) Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264). U.S. National Institutes of Health.
• [2] Sacituzumab Govitecan: First Approval. Drugs. 2020 Jul;80(10):1019-1025.
• [3] Clinical pipeline report, company report or official report of Biocytogen